Latest
Coherus sells its last biosimilar Udenyca to Intas for up to $558M as company homes in on novel cancer meds
Read ArticleCalciMedica Announces Positive Topline Data from Phase 2b CARPO Trial of Auxora™ in Acute Pancreatitis (AP)
Read ArticleCellworks Personalized Therapy Biosimulation Study Produces Superior OS and DFS Predictions for Gastroesophageal Cancer Patients
Read ArticleCalciMedica Announces Presentation of a Preclinical Study of Auxora in Acute Kidney Injury at the AKI & CRRT Conference
Read ArticleCalciMedica Announces FDA Clearance of IND Application for Phase 2 Trial of Auxora™ for Treatment of Severe Acute Kidney Injury
Read ArticleCoherus Announces Positive Final Overall Survival Results of JUPITER-02 Phase 3 Trial Evaluating Toripalimab in Nasopharyngeal Car
Read ArticleOncoResponse Awarded $13 Million in Funding from CPRIT to Advance Cancer Immunotherapy
Read Article